Phase 1b KEYNOTE-200 (STORM):
|
|
- Pearl Shields
- 5 years ago
- Views:
Transcription
1 Phase 1b KEYNOTE-2 (STORM): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients Hardev S. Pandha 1, Kevin J. Harrington 2, Christy Ralph 3, Alan Melcher 2, Brendan Curti 4, Rachel Sanborn 4, Charles Rudin 5, Jonathan Rosenberg 5, Sumati Gupta 6, Wallace Akerly 6, Emmett Schmidt 7, David Kaufman 7, Mark Grose 8, Bronwyn Davies 8, Roberta Karpathy 8, Darren Shafren 8 1
2 I have the following financial relationships to disclose: Consultant: Abbvie, BMS, Celgene, G1 Therapeutics, Novartis Scientific advisory board: Harpoon Therapeutics I will discuss the following off label use and/or investigational use in my presentation: CVA21 2
3 Cytoplasmic replication of CVA21 in non-muscle invasive bladder cancer 3
4 Implant human SK-Mel 28 Treatment CAVATAK or saline Sacrifice mice and excise tumor Day Day 14 3h 6h 24h 72h x Tumor gene profiling SCID Balb/C CAVATAK or saline IV (tail vein) Excise tumor for viral and cellular gene profiling 4
5 γ Saline Tumor gene expression CVA-21 Tumor CVA21 replication 15 Saline-CXCL1 15 CAVATAK-CXCL1 TCID 5 equivalent/mg tumor CXCL1 Normalised gene-fold changes h 6h 24h 72h Time post-saline administration (h) Saline-PD-L1 Normalised gene-fold changes h 6h 24h 72h Hours post-cavatak administration CAVATAK-PD-L Time post-cavatak administration (h) PD-L1 Normalised gene-fold changes Normalised gene-fold changes h 6h 24h 72h Time post-saline administration (h). 3h 6h 24h 72h Time post-cavatak administration (h) 5
6 6
7 Tail vein injection 3LL-hICAM-1 cells Treatment iv CVA21 or saline + ip anti-pd-1 or control mab Observation: Sacrifice 2% weight loss or labored breathing Day LL-hICAM-1 cells (i.v tail vein) CVA21 anti-pd-1 mab * 3LL-ICAM-1 cells are murine NSCLC 3LL cells stably transfected to express human ICAM-1 to allow CAVATAK binding and cell infection 7
8 Kaplan-Meier Survival analysis* Control Ab + Saline Control Ab + CVA21 Control Ab + Saline anti-m-pd-1 + Saline anti-m-pd-1 + Saline anti-m-pd-1 + CVA Percent survival 5 Percent survival 5 Percent survival 5 P = NS Days ** P = Days *P = Days *n=1, sacrifice 2% weight loss or labored breathing 8
9 Part A / CVA21 Part B / CVA21 + pembrolizumab (Monotherapy) (Combination) Advanced melanoma, prostate, NSCLC or bladder cancer, sero-negative CVA21 days 1,3,5,22,43,64,85,16,127,148 Cohort 1 1 x1 8 TCID 5 n=3 Cohort 2 3 x 1 8 TCID 5 n=3 Cohort 3 1 x 1 9 TCID 5 Mandatory lesion biopsy (Day 8) Melanoma, NSCLC, Bladder And Prostate cancer n=3 each No DLT s CVA21 days 1,3,5,8,29,5,71,92,113,134,155 + pembrolizumab (2mg) every 3 weeks starting Day 8 Cohort Expansion NSCLC (~n=4) CVA21 (1 x1 9 TCID 5 ) + pembrolizumab Cohort 1 (n= 3) NSCLC or bladder cancer CVA21 (1 x1 8 TCID 5 ) + pembrolizumab Cohort 2 (n = 3) NSCLC or bladder cancer CVA21 (3 x1 8 TCID 5 ) + pembrolizumab Cohort 3 (n = 3) NSCLC or bladder cancer CVA21 (1 x1 9 TCID 5 ) + pembrolizumab Cohort Expansion Bladder CA (~n=4) CVA21 (1 x1 9 TCID 5 ) + pembrolizumab 9
10 Part A: Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant prostate cancer (CRPC) which are metastatic, or (4) Stage IIIC or Stage IV melanoma. Part B: Histologically or cytologically-confirmed advanced (1) NSCLC, (2) urothelial carcinoma. Part A: All subjects in Cohort 3 or P2D cohort must have a lesion accessible for FNA or core biopsy or open biopsy on Day 8 of the first treatment cycle. Part B: All subjects in Cohort 3 or P2D cohort must have either archival tissue available or a lesion accessible for mandatory core biopsy or open biopsy prior to treatment. Day 15 biopsy is requested but optional ECOG Performance Scale -1 Part B (Part A: -2). Life expectancy >3 months. Measureable disease based on RECIST
11 Primary Objectives Part A To determine if CVA21 given intravenously is capable of tracking to malignant tumors. To establish a safe dose schedule of CVA21 for subsequent Phase 2 clinical trials. To describe the safety profile for intravenously-administered CVA21. Part B To assess and describe the safety profile of intravenous CVA21 and intravenous pembrolizumab in solid tumors of metastatic bladder cancer and NSCLC. To assess efficacy of the combination of CVA21 and intravenous pembrolizumab. in solid tumors of metastatic bladder cancer and NSCLC. 11
12 N=18 Related to CVA21 n (%) Grade 1 Grade 2 Grade 3 Grade 4-5 Total Fatigue 3 (17%) 2 (11%) 5 (28%) Pyrexia 4 (22%) 1 (6%) 5 (28%) Flu-like illness 2 (11%) 1 (6%) 3 (17%) Lethargy 3 (17%) 3 (17%) Headache 1 (6%) 1 (6%) Abdominal distension 1 (6%) 1 (6%) Diarrhea 1 (6%) 1 (6%) Nasopharyngitis 1 (6%) 1 (6%) Arthralgia 1 (6%) 1 (6%) Myalgia 1 (6%) 1 (6%) Dry skin 1 (6%) 1 (6%) 12
13 1 8 AUC 48 hours post-infusion (CVA21 RNA copies/ml serum) Cohort 1: Cohort 2: Cohort 3: 1 8 TCID 5 3x1 8 TCID TCID 5 *Area under the curve (AUC) exposure over 48hr following the first infusion of CVA21 13
14 Prostate cancer Melanoma NSCLC Bladder cancer CVA21 RNA copies/mg tumour RNA Patient Number Limit of detection (15 copies/mg RNA) Bone Bone Lymph Node Abdominal Wall Soft tissue, chest Chest Wall Lung iliac node Thigh Liver *Day 8 biopsy from Cohort 3 patients administered three infusions of 1 9 TCID 5 of CVA21 14
15 Control Anti-enteroviral protein Pt 2-5 (IVM1c) Nucleus Cytoplasmic CVA21 viral proteins Pt 3-6 (IVM1c) *Day 8 biopsy from Cohort 3 patients administered three infusions of 1 9 TCID 5 of CVA21 15
16 Best percentage change in the target lesions sum of diameters relative to baseline Melanoma Castrate-resistant prostate cancer NSCLC Metastatic bladder cancer PD SD PR *irrecist criteria: Preliminary data, investigator assessed + First response assessment at Day 42 16
17 NSCLC 3-2 Melanoma 2-1 Bladder CVA21 RNA copies/ml serum Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Prostate Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum NSCLC Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Bladder Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Bladder Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Prostate Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 CVA21 RNA copies/ml serum Melanoma Secondary viral replication Post -infusion viral load 48h post-infusion #1 48h post-infusion #2 72h post-infusion #3 17
18 Single IV dose (Phase 1) Multi IV dose (KEYNOTE 2) Anti-CAVATAK neutralising antibody titre CVA21 infusion Pt 24 Pt15 Pt26 Pt Pos/Neg Cut-off Anti-CAVATAK neutralising antibody titre CVA21 infusions Days post-cavatak infusion Days post-cavatak infusion 18
19 Enrolment complete IV delivery of CVA21 was generally well tolerated no grade 3 or 4 related AE s with a median of 6 CVA21 infusions per patient no dose-limiting toxicities CVA21 tumor targeting in patients with melanoma, NSCLC and bladder cancer patients in Cohort 3 was confirmed detection of CVA21 viral RNA in tumor biopsies at study day 8 viral replication by IHC in melanoma tumor biopsies Of the 15 patients from Cohorts 1-3 eligible for investigator best overall response assessment, 1 PR, 1 SD and 4 PD were observed Serum viral loads suggest potential secondary viral replication events 19
20 IV CVA21 days 1,3,5,8,29,5,71,92,113,134,155 + IV pembrolizumab (2mg) every 3 weeks starting Day 8 Cohort 1 (n= 3) NSCLC or bladder cancer CVA21 (1 x1 8 TCID 5 ) + pembrolizumab Cohort 2 (n = 3) NSCLC or bladder cancer CVA21 (3 x1 8 TCID 5 ) + pembrolizumab Recruitment complete Recruitment complete Cohort 3 (n= 3) NSCLC or bladder cancer CVA21 (1 x1 9 TCID 5 ) + pembrolizumab Recruitment complete No DLT s Cohort Expansion NSCLC (~n=4 +/- prior checkpoint) CVA21 (1 x1 9 TCID 5 ) + pembrolizumab Cohort Expansion Bladder CA (~n=4 +/- prior checkpoint) CVA21 (1 x1 9 TCID 5 ) + pembrolizumab 2
21 N=1 Related to CVA21 n(%) Related to Pembrolizumab n(%) Grade 1 Grade 2 Grade 3 Grade 4-5 Grade 1 Grade 2 Grade 3 Grade 4-5 No DLT s reported Fatigue 3 (3%) 2 (2%) Nausea 2 (2%) 1 (1%) 1 (1%) Pyrexia 3 (3%) 1 (1%) Myalgia 2 (2%) Headache 2 (2%) Hypotension 1 (1%) 1 (1%) Diarrhea 1 (1%) 1 (1%) Dizziness 2 (2%) Vomiting 1 (1%) 1 (1%) Constipation 1 (1%) Chills 1 (1%) Hyponatremia 1 (1%) Flu-like illness 1 (1%) Malaise 1 (1%) 21
22 Cohort CVA21 Dose (TCID5) 1 1 x x 1 8 Patient No. Tumor Type 121 NSCLC 67 M 151 Bladder 73 M Age Gender Prior Therapy Response (Day)* surgery (2), chemotherapy (5), radiotherapy surgery (11), chemotherapy (2), radiotherapy (2) CVA21 Doses Pembrolizumab Doses PD (Day 114) 8 5 PD (Day 118) Bladder 58 M surgery (3), chemotherapy (2) PD (Day 83) NSCLC 62 M 154 Bladder 68 F surgery, chemotherapy (2), radiotherapy surgery (4), chemotherapy (2), immunotherapy (BCG, atezolizumab), other 122 NSCLC 76 F chemotherapy (2), radiotherapy 132 Bladder 8 M 3 1 x NSCLC 66 M surgery (13), radiotherapy, chemotherapy (5), immunotherapy (BCG, atezolizumab) chemotherapy (2), radiotherapy (2), immunotherapy (anti-b7h3, anti- PDL1, ipilimumab, nivolumab) PD (Day 92) ** 7 4 Withdrawn due to unrelated grade 3 sepsis (Day 19) Withdrew consent (Day 25) PD (Day 29) 4 2 ongoing (Day 44) NSCLC 81 M chemotherapy, immunotherapy (nivolumab) ongoing (Day 21) Bladder 61 M chemotherapy, surgery (2) ongoing (Day 15) 4 1 *First response assessment at Day 92; **Clinical progression only 22
23 Reciprocal Log 1 anti-cva21 neutralising antibody titer 2 2 Part A: CVA Pos/Neg cut-off Reciprocal Log 1 anti-cva21 neutralising antibody titer Part B: CVA21+ pembrolizumab + pembrolizumab Pos/Neg cut-off Study Days Study Days 23
24 Enrollment in Part A (monotherapy) is complete with no DLTs observed Successful systemic CVA21 tumor targeting and findings of potential secondary CVA21 replication (Part A) Evidence of tumor stabilization and response (Part A) At present, the combination of intravenous CVA21 and pembrolizumab (Part B) has been generally well-tolerated in heavily pre-treated patients with or without prior immune checkpoint therapy Enrollment in Part B (combination) Cohorts 1,2 and 3 complete. Expansion cohort currently recruiting One grade 3 CVA21-related hyponatremia with no DLT for the combination of CVA21 and pembrolizumab Comparable host anti-cva21 immune responses in the presence or absence of pembrolizumab Intravenous delivery of CVA21 is able to target metastatic lesions with the potential to upregulate PD-L1 expression during the viral replication process 24
25 The investigators, patients, and study staff who are contributing to this study; Viralytics R&D and clinical teams Support for this study was provided by Viralytics Ltd. Merck & Co. 25
Disclosures Information Brendan D. Curti, MD
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy
More informationPoster No: 319. Dr Nicola Annels University of Surrey, UK
Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non- Muscle Invasive Bladder (NMIBC) Cancer using Intravesical Coxsackievirus A21. Poster No: 319 Dr Nicola Annels University of Surrey,
More informationAt the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour
More informationOncolytic Immunotherapies for Difficult-to-Treat Cancers. Annual General Meeting 23 rd November 2016
1 Oncolytic Immunotherapies for Difficult-to-Treat Cancers Annual General Meeting 23 rd November 2016 Disclaimer 2 Certain statements made in this presentation are forward looking statements within the
More informationCoxsackievirus A21: The basic facts
Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents
More informationCoxsackievirus A21 as an oncolytic agent for the control of human cancer
Coxsackievirus A21 as an oncolytic agent for the control of human cancer Dr Gough G. Au PhD Conjoint Research Fellow The University of Newcastle Australia Viralytics Ltd. Viruses can be used to treat cancer
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationProvidence Cancer Center, Portland, OR; 2 Oncology Specialists, Chicago, IL; 3 John Wayne Cancer InsPtute, Santa Monica, CA; 4
The MITCI (Phase 1b) study: A novel immunotherapy combina>on of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma pa>ents with or without previous immune checkpoint therapy
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAt the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Investment highlights Lead investigational product CAVATAK kills cancer cells with a bio-selected form of the common cold virus
More informationB. G. Redman University of Michigan, Ann Arbor, MI. J. A. Thompson University of Washington, Seattle, WA
Identification of a well-tolerated outpatient regimen of intravenous recombinant human interleukin-2 (IL-2) in patients with metastatic melanoma and metastatic renal cell carcinoma J. A. Thompson University
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationOncolytic Viruses: Reovirus
T S X : O N C N A S D A Q : O N C Y International Society for Biological Therapy of Cancer 2008 Oncology Biologics Development Primer Oncolytic Viruses: Reovirus REOLYSIN - mode of action REOLYSIN contains
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationDCC-2618, a novel pan-kit and PDGFR
DCC-2618, a novel pan-kit and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST) N. Somaiah, A. Razak, M. Gordon, F.
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationKEYNOTE 695: TAVO Phase 2b Melanoma Trial Preliminary Data for SITC November 6, 2018
KEYNOTE 695: TAVO Phase 2b Melanoma Trial Preliminary Data for SITC 2018 November 6, 2018 1 FORWARD-LOOKING STATEMENTS To the extent statements contained in the following presentations are not descriptions
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationTwo roads for oncolytic immunotherapy development
Kaufman and Bommareddy Journal for ImmunoTherapy of Cancer (2019) 7:26 https://doi.org/10.1186/s40425-019-0515-2 COMMENTARY Two roads for oncolytic immunotherapy development Howard L. Kaufman 1,2* and
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationPhase 1 Trial of ALN-VSP in Cancers Involving the Liver. Annual Meeting of the Controlled Release Society August 2, 2011
Phase 1 Trial of ALN-VSP in Cancers Involving the Liver Annual Meeting of the Controlled Release Society August 2, 2011 Agenda ALN-VSP: Background Phase 1 Trial Study Design Safety Data Tumor Response
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIs Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015
Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationEncouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST)
2017 ESMO Proffered Paper Encouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST) F Janku, A Razak, M Gordon, D Flynn, M Kaufman,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUpdate on new agents in Gastrointestinal Tumor (GIST)
Update on new agents in Gastrointestinal Tumor (GIST) Albiruni R Abdul Razak Medical Oncology Sarcoma Site Lead Princess Margaret Cancer Centre/Mount Sinai Hospital 21 st October 2017 1 Disclosure Research
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationTitle A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho
Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma,
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationpatients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease
patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease First, perc agreed with CGP that the diagnosis of urothelial
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationFuture Therapeutic Developments in Head and Neck Cancer
Future Therapeutic Developments in Head and Neck Cancer Professor Kevin Harrington Joint Head of Division of Radiotherapy and Imaging The Institute of Cancer Research/The Royal Marsden NIHR Biomedical
More informationLIGAND-INDUCIBLE, PROSTATE STEM CELL ANTIGEN (PSCA)-DIRECTED GoCAR-T CELLS IN ADVANCED SOLID TUMORS: PRELIMINARY RESULTS FROM A DOSE ESCALATION STUDY
LIGAND-INDUCIBLE, PROSTATE STEM CELL ANTIGEN (PSCA)-DIRECTED GoCAR-T CELLS IN ADVANCED SOLID TUMORS: PRELIMINARY RESULTS FROM A DOSE ESCALATION STUDY Carlos R. Becerra, 1 Pamela Hoof, 1 Scott Paulson,
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationPresenter Disclosure Information
Phase 1b: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus bempegaldesleukin (NKTR-214) [CD122-biased agonist] in patients (pts) with locally advanced or metastatic
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More information